Heart FailurePhase 3HEART-FIDNCT03037931
Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study
A Phase 3 study testing Ferric Carboxymaltose in people with Heart Failure and Iron-deficiency, run by American Regent, Inc. at 345 sites in 13 countries.
Trial summary
The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo in the treatment of participants in heart failure with a reduced ejection fraction and with iron deficiency Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Heart Failure, Iron-deficiency
- What is being tested?
- Ferric Carboxymaltose
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 3,065 participants
- Where
- 345 sitesin 13 countries
- Study dates
- 15 Mar 2017to 2 Feb 2023
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult (≥18 years of age) able to provide signed, written informed consent.
- Stable heart failure (NYHA II-IV) on maximally-tolerated background therapy (as determined by the site Principle Investigator) for at least 2 weeks prior to randomization.
- Able and willing to perform a six-minute walk test (6MWT) at the time of randomization.
- Reduced left ventricular ejection fraction. Assessment must be performed at least 12 weeks after major cardiac surgical intervention including coronary artery bypass graft (CABG), valvular repair/replacement, or cardiac resynchronization therapy (CRT) device implantation.
- Left ventricular ejection fraction ≤ 40% obtained during the screening visit OR either of the following i. Historical value of ejection fraction ≤ 40% within 24 months of screening visit ii. Historical value of ejection fraction ≤ 30% within 36 months of screening visit
- Hemoglobin >9.0 g/dL and < 13.5 g/dL (females) or <15.0 g/dL (males) within 28 days of randomization.
- Serum ferritin <100 ng/mL or 100 to 300 ng/mL with TSAT <20%.Patients with screening ferritin <15 ng/mL must have documentation of an appropriate evaluation, as determined by the Principle Investigator, within 3 months of screening and prior to randomization.
- Either documented hospitalization for heart failure within 12 months of enrollment or elavated N-terminal-pro-brain natriuretic peptide (NT-proBNP) within 90 days of randomization. a. For patients in normal sinus rhythm: N-terminal-pro-brain natriuretic peptide (NT- proBNP) > 600 pg/mL (or BNP >200 pg/mL) . b . For patients in atrial fibrillation: NT-proBNP >1000 pg/mL (or BNP >400 pg/mL) .
Who cannot join
- Known hypersensitivity reaction to any component of FCM.
- History of acquired iron overload, or the recent receipt (within 3 months) of erythropoietin stimulating agent, IV iron therapy, or blood transfusion.
- Acute myocardial infarction, acute coronary syndrome, transient ischemic attack, or stroke within 30 days of enrollment.
- Uncorrected severe aortic stenosis, severe valvular regurgitation (except mitral regurgitation due to left ventricular dilatation without planned intervention), or left ventricular outflow obstruction requiring intervention.
- Current atrial fibrillation or atrial flutter with a mean ventricular response rate >100 per minute (at rest).
- Current or planned mechanical circulatory support or heart transplantation.
Show all 14Show fewer
- Hemodialysis or peritoneal dialysis (current or planned within the next 6 months).
- Documented liver disease, or active hepatitis (i.e. alanine transaminase or aspartate transaminase >3 times the upper limit of normal range).
- Current or recent (within 3 years) malignancy with exception of basal cell carcinoma or squamous cell carcinoma of the skin, or cervical intraepithelial neoplasia.
- Active gastrointestinal bleeding.
- Female participant of child-bearing potential who is pregnant, lactating, or not willing to use adequate contraceptive precautions during the study and for up to 5 days after the last scheduled dose of study medication.
- Inability to return for follow up visits within the necessary windows
- Concurrently in a study with investigational product.
- No participants with Current Coronavirus Disease-19 (COVID-19) Infection into the study.
Trial locations and contacts
345 sites in 13 countries.
345 sites in 13 countries
United States188 sites
Abington Memorial Hospital
Abington, Pennsylvania, 19001
Advanced Cardiovascular LLC
Alexander City, Alabama, 35010
Alexandria Cardiology Clinic
Alexandria, Louisiana, 71301
Amarillo Hearth Clinical Research Institute, Inc.
Amarillo, Texas, 79106
PharmaTex Research
Amarillo, Texas, 79106
Alaska Heart & Vascular Institute
Anchorage, Alaska, 99508
Anne Arundel Health System Research Institute
Annapolis, Maryland, 21401
Asheville Cardiology Associates
Asheville, North Carolina, 28803
Piedmont Heart Institute - Athens
Athens, Georgia, 30606
Piedmont Heart Institute
Atlanta, Georgia, 30309
Advanced Cardiovascular, LLC
Auburn, Alabama, 36830
University Cardiology Associates, LLC
Augusta, Georgia, 30901
Augusta University
Augusta, Georgia, 30912
Sinai Hospital of Baltimore
Baltimore, Maryland, 21215
Suburban Hospital
Bethesda, Maryland, 20814
Westside Medical Associates of Los Angeles
Beverly Hills, California, 90211
Saint Luke's Boise Medical Center
Boise, Idaho, 83712
Massachusetts General Hospital
Boston, Massachusetts, 02114
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Cardiology Associates of South Florida
Boynton Beach, Florida, 33472
Cardiovascular & Vein Center of Florida
Bradenton, Florida, 34209
New York Presbyterian Brooklyn Methodist Hospital
Brooklyn, New York, 11215
The University of Vermont Medical Center
Burlington, Vermont, 05401
Penn State Health Holy Spirit Medical Center Geisinger - Cardiology
Camp Hill, Pennsylvania, 17011
Aultman Cardiology Clinical Trials
Canton, Ohio, 44710
Harbor-UCLA Medical Center
Carson, California, 90509
Trinity Medical WNY, PC
Cheektowaga, New York, 14227
Mount Sinai Hospital Medical Center - Department of Cardiology
Chicago, Illinois, 60608
Innovative Research of West Florida, Inc.
Clearwater, Florida, 33756
The MetroHealth System
Cleveland, Ohio, 44109
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Prisma Health
Columbia, South Carolina, 29203
The Ohio State University
Columbus, Ohio, 43210
Verde Valley Medical Center
Cottonwood, Arizona, 86326
Valley Clinical Trials, Inc.
Covina, California, 91723
Dallas VA Medical Center
Dallas, Texas, 75216
Cardiovascular Research Institute of Dallas
Dallas, Texas, 75231
Southwest Family Medicine Associates
Dallas, Texas, 75235
Baylor University Medical Center
Dallas, Texas, 75246
Danbury Hospital
Danbury, Connecticut, 06810
Avail Clinical Research, LLC
DeLand, Florida, 32720
Duke University Heart Failure Research
Durham, North Carolina, 27710
Monmouth Cardiology Associates, LLC
Eatontown, New Jersey, 07724
Riverside Clinical Research
Edgewater, Florida, 32132
TriWest Research Associates, LLC
El Cajon, California, 92020
North Ohio Heart Center
Elyria, Ohio, 44035
Englewood Health
Englewood, New Jersey, 07631
Providence Regional Medical Center Everett
Everett, Washington, 98201
Medicoricium, LLC
Fairview Heights, Illinois, 62208
NECCR Prima Care Research, LLC
Fall River, Massachusetts, 02721
Piedmont Heart Institute Fayetteville
Fayetteville, Georgia, 30214
Advanced Heart & Vascular Institute of Hunterdon
Flemington, New Jersey, 08822
Sparks Regional Medical Center
Fort Smith, Arkansas, 72901
Parkview Research Center
Fort Wayne, Indiana, 46845
Texas Health Research & Education Institute
Fort Worth, Texas, 76104
Stern Cardiovascular Foundation
Germantown, Tennessee, 38138
Genesys Regional Medical Center
Grand Blanc, Michigan, 48439
Medication Management, LLC
Greensboro, North Carolina, 27401
Self Regional Hospital Research Center
Greenwood, South Carolina, 29646
Hackensack University Medical Center
Hackensack, New Jersey, 07601
Heart Clinic of Hammond
Hammond, Louisiana, 70403
Wake Forest University Health Sciences
High Point, North Carolina, 27262
Memorial Regional Hospital
Hollywood, Florida, 33021
Cardiovascular Institute of the South
Houma, Louisiana, 70360
Texas Heart Institute
Houston, Texas, 77030
California Heart Specialists
Huntington Beach, California, 92648
Franciscan Physician Network - Indiana Heart Physicians
Indianapolis, Indiana, 46237
St. Vincent Medical Group
Indianapolis, Indiana, 46260
St. Vincent's Healthcare - Riverside
Jacksonville, Florida, 32204
UF Health Jacksonville
Jacksonville, Florida, 32209
St. Vincent's Healthcare - Southside Recruiting
Jacksonville, Florida, 32216
Mayo Clinic Florida
Jacksonville, Florida, 32224
NEA Baptist Clinic
Jonesboro, Arkansas, 72401
Western Michigan University Homer Stryker M.D. School of Medicine
Kalamazoo, Michigan, 49008
Houston Heart & Vascular Associates
Kingwood, Texas, 77339
Tennova Healthcare-Turkey Creek Medical Center
Knoxville, Tennessee, 37934
First Valley Medical Group
Lancaster, California, 93534
Lancaster General Hospital
Lancaster, Pennsylvania, 17602
Carolina Heart Specialists
Lancaster, South Carolina, 29720
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
Red Rock Clinical Research, LLC
Las Vegas, Nevada, 89146
Nebraska Heart Institute
Lincoln, Nebraska, 68526
Arkansas Heart Hospital
Little Rock, Arkansas, 72211
South Denver Cardiology Associates, PC
Littleton, Colorado, 80120
Healthcare Partners Affiliation Medical Group
Long Beach, California, 90806
Axis Clinical Trials
Los Angeles, California, 90036
Caprock Cardiac Center Research Institute, Inc.
Lubbock, Texas, 79410
Angelina Medical Research, LLC
Lufkin, Texas, 75904
Duke Cardiology of Lumberton
Lumberton, North Carolina, 28358
Stroobants Cardiovascular Center
Lynchburg, Virginia, 24501
Georgia Arrhythmia Consultants and Research Institute
Macon, Georgia, 31201
Mercer University
Macon, Georgia, 31201
Marshfield Clinic
Marshfield, Wisconsin, 54449
North Dallas Research Associates
McKinney, Texas, 75069
North Texas Research Associates
McKinney, Texas, 75701
ProLive Medical Research
Miami, Florida, 33130
Cordova Research Institute, LLC
Miami, Florida, 33155
Med-Care Research
Miami, Florida, 33165
ITB Research
Miami, Florida, 33173
Vista Health Research
Miami, Florida, 33176
Empire Clinical Research, LLC
Miami Lakes, Florida, 33016
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Allina Health System, dba Abbott Northwestern Hospital
Minneapolis, Minnesota, 55407
Trinity Health Center - Medical Arts
Minot, North Dakota, 58701
St. Joseph Heritage-Healthcare
Mission Viejo, California, 92691
IMC/Diagnostic & Medical Clinic
Mobile, Alabama, 36604
University of South Alabama
Mobile, Alabama, 36617
Monroe Biomedical Research
Monroe, North Carolina, 28112
Crossroads Clinical Research, Inc.
Mooresville, North Carolina, 28117
Indiana University Health Ball Memorial Hospital, Inc.
Muncie, Indiana, 47303
Saint Peter's University Hospital
New Brunswick, New Jersey, 08901
Tulane Heart & Vascular Institute
New Orleans, Louisiana, 70112
Ochsner Health System
New Orleans, Louisiana, 70121
Mount Sinai Hospital
New York, New York, 10029
Christiana Care
Newark, Delaware, 19718
Saint Michael's Medical Center
Newark, New Jersey, 07102
Rutgers New Jersey Medical School
Newark, New Jersey, 07103
Radin Cardiovascular Medical Group, Inc.
Newport Beach, California, 92663
Riverside Cardiology Specialists
Newport News, Virginia, 23601
Sentara Norfolk General Hospital
Norfolk, Virginia, 23507
North Kansas City Hospital
North Kansas City, Missouri, 64116
Valley Clinical Trials, Inc.
Northridge, California, 91325
Parkway Cardiology Associates, PC
Oak Ridge, Tennessee, 37830
South Oklahoma Heart Research, LLC
Oklahoma City, Oklahoma, 73135
CHI Health Research Center
Omaha, Nebraska, 68124
Florida Hospital Transplant Institute
Orlando, Florida, 32804
Cardiology Partners Clinical Research Institute
Palm Beach Gardens, Florida, 33410
Springfield Medical Center
Panama City, Florida, 32401
Pasadena Clinical Research
Pasadena, California, 91105
Broward Research Center
Pembroke Pines, Florida, 33024
South Florida Research Solutions, LLC
Pembroke Pines, Florida, 33026
Cardiology Consultants
Pensacola, Florida, 32501
Avanza Medical Research Center
Pensacola, Florida, 32503
Drexel University
Philadelphia, Pennsylvania, 19102
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104
University of Pennsylvania - Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104
Pinehurst Medical Clinic, Inc.
Pinehurst, North Carolina, 28374
V.A. Pittsburgh Healthcare System
Pittsburgh, Pennsylvania, 15240
AtlantiCare Regional Medical Center
Pomona, New Jersey, 08240
Eugene Soroka, MD Inc.
Port Hueneme, California, 93041
NC Heart & Vascular Research
Raleigh, North Carolina, 27607
WakeMed Health and Hospitals
Raleigh, North Carolina, 27610
Black Hills Cardiovascular Research, a department of Rapid City Regional Hospital, Inc.
Rapid City, South Dakota, 57701
Reid Physician Associates / Reid Health
Richmond, Indiana, 47374
Hunter Holmes McGuire V.A. Medical Center - Cardiology Div. (111J)
Richmond, Virginia, 23249
VCU Medical Center
Richmond, Virginia, 23298
The Valley Hospital
Ridgewood, New Jersey, 07450
Carilion Medical Center
Roanoke, Virginia, 24014
Mayo Clinic
Rochester, Minnesota, 55905
Rochester General Hospital
Rochester, New York, 14621
Michigan CardioVascular Institute at Covenant Medical Center
Saginaw, Michigan, 48602
South Texas Cardiovascular Consultants, PLLC
San Antonio, Texas, 78201
VA San Diego Health Care System
San Diego, California, 92161
North Ohio Heart Center
Sandusky, Ohio, 44870
Maine Medical Partners Maine Health Cardiology
Scarborough, Maine, 04074
Swedish Heart & Vascular-Advanced Cardiac Support Program
Seattle, Washington, 98122
Louisiana Heart Center
Slidell, Louisiana, 70458
Atlanta Vanguard Research Institute
Smyrna, Georgia, 30082
Cardio Metabolic Institute
Somerset, New Jersey, 08873
Beacon Medical Group Advanced Cardiovascular Specialists
South Bend, Indiana, 46601
Providence Sacred Heart Medical Center & Children's Hospital
Spokane, Washington, 99204
Heart House Research Foundation
Springfield, Ohio, 45505
St. Louis Heart & Vascular, PC
St Louis, Missouri, 63136
Professional Health Care of Pinellas
St. Petersburg, Florida, 33713
Stamford Hospital
Stamford, Connecticut, 06904
Richmond University Medical Center
Staten Island, New York, 10310
Stony Brook University Hospital
Stony Brook, New York, 11794-7007
Clinical Research Institute of Arizona, LLC
Surprise, Arizona, 85374
CHI Franciscan Research Center
Tacoma, Washington, 98405
Holy Name Medical Center
Teaneck, New Jersey, 07666
Baylor Scott & White Medical Center
Temple, Texas, 76508
Carondelet Heart and Vascular Institute - Cardiology East
Tucson, Arizona, 85710
Cardiology Associates Research, LLC
Tupelo, Mississippi, 38801
PharmaTex Research
Tyler, Texas, 75701
The University of Texas Health Center at Tyler
Tyler, Texas, 75708
Indian River Medical Center
Vero Beach, Florida, 32960
Walla Walla Clinic
Walla Walla, Washington, 99362
ProHealth Care Inc / Waukesha Memorial Hospital
Waukesha, Wisconsin, 53188
Cardiology Partners Clinical Research Institute
Wellington, Florida, 33449
Wenatchee Valley Hospital & Clinics
Wenatchee, Washington, 98801
Interventional Cardiology Medical Group
West Hills, California, 91307
Advanced Clinical Research/Intermountain Heart Center PC
West Jordan, Utah, 84088
Circuit Clinical
West Seneca, New York, 14224
Wichita Falls Heart Clinic
Wichita Falls, Texas, 76301
Northtowns Cardiology, PLLC
Williamsville, New York, 14221
Alfieri Cardiology
Wilmington, Delaware, 19803
PMG Research of Wilmington
Wilmington, North Carolina, 28401
Selma Medical Associates
Winchester, Virginia, 22601
Canada25 sites
Manna Research Inc., Burlington South
Burlington, Ontario, L7R 1A4
University of Calbary
Calgary, Alberta, T2N 4Z6
Cambridge Cardiac Care Center
Cambridge, Ontario, N1R 6V6
Vizel Cardiac Research
Cambridge, Ontario, N1R 7R1
University of Alberta Hospital
Edmonton, Alberta, T6G 2B7
South Edmonton Cardiology Consultants
Edmonton, Alberta, T6L 6K3
Royal Alexandria Hospital
Edmonton, Alberta
Nova Scotia Health Authority
Halifax, Nova Scotia, B3H 3A7
Clinique de Cardiologie de Lévis
Lévis, Quebec, G6V 4Z5
London Health Sciences Center (LHSC)
London, Ontario, N6A 5A5
G.A. Research Associates, Ltd.
Moncton, New Brunswick
Montreal Heart Institute
Montreal, Quebec, H1T 1C8
McGill University Health Centre (MUHC)
Montreal, Quebec, H4A 3J1
Fraser Clinical Trials
New Westminster, British Columbia, V3L 3W4
Institut Universitaire de Cardiologie et de Pneumologie de Quebec - Université Laval
Québec, Quebec, G1V 4G5
CISSS de Chaudière-Appalaches (CISSS-CA), site Hôpital St-Georges
Saint-Georges, Quebec, G5Y 4T8
Recherche Medical St-Jerome Inc.
Saint-Jérôme, Quebec, J7Z 5T3
Royal University Hospital
Saskatoon, Saskatchewan, S7N 0W8
Health Sciences Centre
St. John's, Newfoundland and Labrador, A1B 3V6
SMH Cardiology Clinical Trials
Surrey, British Columbia, V3V 0C6
St. Michael's Hospital
Toronto, Ontario, M5B 1W8
Sinai Health System - Mount Sinai Hospital
Toronto, Ontario, M5G 1X5
Centre Intégré Universitaire de Santé et de Services Sociaux de la Mauricie-et-du-centre-du-Quebec
Trois-Rivières, Quebec, G8Z 3R9
St. Paul's Hospital
Vancouver, British Columbia, V6E 1M7
Victoria Heart Institute Foundation
Victoria, British Columbia, V8R 4R2
Ukraine24 sites
Municipal non-profit enterprise "Ivano-Frankivsk Regional Clinical Cardiological Center"
Ivano-Frankivsk, 76025
Military and Medical Clinical Center of the Northern Region (Military Unit A-3306) Cardiology Department
Kharkiv, 61058
Scientific Medical Complex "University Clinic" of Kharkiv
Kharkiv, 61157
MNCE "City Hospital № 8" of Kharkiv City Council, Cardiology Department №2
Kharkiv, 61176
Communal Institution "Kryvyi Rih City Hospital №9" of Kryvyi Rih City Council
Kryvyi Rih, 50031
Municipal Non-Profit Enterprise "Consultative and Diagnostic centre" of Pechersk District of Kiyv
Kyiv, 01103
"Oleksandrivska Clinical Hospital of Kyiv" of executive authority Kyiv City
Kyiv, 01601
Communal nonprofit enterprise "Oleksandrivska Clinical Hospital of Kyiv
Kyiv, 01601
Communal non-profit enterprise Kyiv City Clinical Hospital №1
Kyiv, 02091
Kyiv City Clinical Hospital of Emergency Aid,
Kyiv, 02166
Kyiv City Clinical Hospital of Emergency Aid
Kyiv, 02166
Kyiv Clinic Railway Hospital №2 of the "Health Care Center" Brach at the PJSC "Ukrainian Railway"
Kyiv, 03049
National Scientific Center Institute of Cardiology of M.D
Kyiv, 03680
State Institution "National Scientific Center "Institute of Cardiology
Kyiv, 03680
Medical Centre of LLC "Medical Centre "CONSILIUM MEDICAL"
Kyiv, 04050
Medical Centre of LLC
Kyiv, 04050
MNPE "Lviv City Clinical Hospital No.5"
Lviv, 79000
Communal Noncommercial Enterprise of Lviv Regional Council "Lviv Regional Clinical
Lviv, 79041
Vinnytsia Regional Clinical Hospital of Veterans of War
Vinnytsia, 21005
"Vinnytsia Regional Clinical Treatment Diagnostic Center of Cardiovascular Pathology"
Vinnytsia, 21029
Communal Non-Profit Enterprise "City
Zaporizhzhya, 69001
Educational and Research Medical Center "University Clinic" at Zaporizhzhia State Medical University of the Ministry of Health of Ukraine,
Zaporizhzhya, 69063
Сommunal Institution "Zaporizhzhia Regional Clinical Hospital" of Zaporizhzhia Regional Council,
Zaporizhzhya, 69600
Communal Enterprise "Hospital №1" of Zhytomyr City Council
Zhytomyr, 10002
Australia16 sites
The Queen Elizabeth Hospital
Adelaide, South Australia, 5011
Royal Adelaide Hospital
Adelaide, 5000
SA Heart
Ashford, South Australia, 5035
Flinders Medical Centre
Bedford Park, South Australia, 5042
Sunshine Coast University Hospital
Birtinya, Queensland, 4575
Cairns Hospital
Cairns, Queensland, 4870
The Prince Charles Hospital
Chermside, Queensland, 4032
Heart Lung Clinic
Darlinghurst, Sydney
Lyell McEwin Hospital
Elizabeth Vale, South Australia, 5112
Royal Hobart Hospital
Hobart, Tasmania, 7000
SWSLHD-Liverpool Hospital
Liverpool, New South Wales, 1871
Macquarie University - Clinical Trials Unit
Macquarie Park, 2109
Core Research Group
Milton, Queensland, 4064
John Hunter Hospital
New Lambton Heights, 2305
Epworth HealthCare Clinical Trials
Richmond, 3121
Gold Coast University Hospital
Southport, Queensland, 4215
Poland16 sites
Oddział Kardiologii WSzS nr 4
Bytom, 41-902
Biokinetica S.A. Przychodnia Józefów
Józefów, 05-410
Centrum Medyczne Linden
Krakow, 30-394
Marcin Ogórek, MD, PhD
Lodz, 94-048
1 Wojskowy Szpital Klininiczny w Lublinie
Lublin, 20-049
Ko-Med Centra Kliniczne
Lublin, 20-362
Szpital Swietej Anny w Miechowie
Miechów, 32-200
Szpital Świętej Anny w Miechowie
Miechów, 32-200
Nowodworskie Centrum Medyczne. Ambulatoryjna Opieka Specjalistyczna
Nowy Dwór Mazowiecki, 05-100
Zespol Opieki Zdrowotnej
Oława, 55-200
Wojewódzki Szpital Zespolony im. L. Rydygiera,Oddzialu Kardiologii i lntensywnej Terapii Kardiologicznej
Torun, 87-100
Uniwersyteckie Centrum Kliniczne
Warsaw, 02-097
Centrum Medyczne K2J2
Wołomin, 05-200
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego
Wroclaw, 50-556
4th Military Hospital
Wroclaw, 50-981
Proximum Centrum Usług Medycznych NZOZ
Wroclaw, 53-428
Bulgaria14 sites
MHAT Puls
Blagoevgrad, 2700
Multiprofile Hospital for Active Treatment: Department of cardiology
Gabrovo, 5300
MHAT Haskovo AD
Haskovo, 6304
Diagnostic - Consultative Center 1 - Lom - EOOD Office of Cardiology
Lom, 3600
Medical Center Medconsult Pleven OOD
Pleven, 5800
МC Hipokrena
Sevlievo, 5400
Diagnostic - Consultative Center XXII - Sofia EOOD, Office of Cardiology
Sofia, 1113
Second Medical Center-Sofia, EEOD - Department of Cardiology
Sofia, 1202
Second Multiprofile Hospital for Active Treatment
Sofia, 1202
5th City Hospital
Sofia, 1233
National Multiprofile Transport Hospital Cardiology Clinic
Sofia, 1233
Medical Center Hera EOOD - Office of Cardiology
Sofia, 1510
Multiprofile Regional Hospital for Active Treatment
Veliko Tarnovo, 5002
Medical Center Velingrad 2017" EOOD, Office of Cardiology
Velingrad, 4600
New Zealand14 sites
Totara Clinical Research, Health New Lynn
Auckland, 0600
North Shore Hospital
Auckland, 0622
Auckland City Hospital
Auckland, 1023
Middlemore Hospital
Auckland, 2025
Christchurch Heart Institute
Christchurch, 8140
Dunedin Hospital
Dunedin, 9016
Hauora Tairāwhiti Department of Cardiology
Gisborne, 4010
Hawke's Bay Hospital
Hastings, 4120
Hutt Hospital
Lower Hutt, 5010
Nelson Hospital
Nelson, 7010
Taranaki Base Hospital
New Plymouth, 4310
Wellington Hospital
Newton, Wellington Region, 6021
Rotorua Hospital
Rotorua
Clinical Horizons NEW ZEALAND LTD
Tauranga, 3112
Russia14 sites
Municipal Autonomous Healthcare Institution "City Clinical Hospital #6
Chelyabinsk, 454017
Municipal Autonomous Healthcare Institution
Chelyabinsk, 454017
Federal State Budgetary Scientific Institution Research Institute for Complex Issues of Cardiovascular Diseases
Kemerovo, 650002
State Budgetary Healthcare Institution of Moscow city "Moscow
Moscow, 117292
Private Medical Institution "Euromedservice
Pushkin, 196603
State Budgetary Institution of Ryazan Region
Ryazan, 390026
JSC Polyclinic Complex
Saint Petersburg, 190013
Saint Petersburg Research Institute of Emergency Medicine n.a. I.I. Dzhanelidze
Saint Petersburg, 192242
Saint Petersburg Research Institute of Emergency Medicine
Saint Petersburg, 192242
LLC X7 Clinical Research
Saint Petersburg, 194156
Saint-Petersburg State Budgetary Institution of Healthcare "Saint Martyr Elizabeth city hospital"
Saint Petersburg, 195257
LLC "Scientific Research Center Eco-Safety"
Saint Petersburg, 196143
State Healthcare Institution
Saratov, 410002
Federal State Budget Educational Institution of Higher Education Saratov State Medical University of the Ministry of Health of Russia
Saratov, 410054
Georgia10 sites
JSC Evex Hospitals,Georgia
Batumi, 6010
Clinic-LJ
Kutaisi, 4600
Aleksandre Aladashvili Clinic LLC
Tbilisi, 0102
Ltd Israel-Georgian Medical Research Clinic "Helsicore"
Tbilisi, 0112
Ltd Pineo Medical Ecosistem
Tbilisi, 0114
Acad. G. Chapidze Emergency Cardiology Center
Tbilisi, 0159
Bokhua Memorial Cardiovascular Center
Tbilisi, 0159
Tbilisi Heart and Vascular Clinic
Tbilisi, 0159
Ltd TIM- Tbilisi Institute of Medicine
Tbilisi, 0160
Georgian-Dutch Hospital
Tbilisi, 0172
Hungary10 sites
Semmelweis Egyetem Városmajori Szív és- Érgyógyászati Klinika Szent Rókus Klinikai Tömb, Kardiológiai
Budapest, 1085
Semmelweis Egyetem Városmajori Szív- és Érgyógyászati Klinika
Budapest, 1122
Debreceni Egyetem Klinikai Központ Kardiológiai Osztály
Debrecen, 4032
Clinexpert Gyöngyös Kft
Gyöngyös, 3200
Zsigmondy Vilmos Harkányi Gyógyfürdȍ Kórház
Harkány, 7815
Bács-Kiskun Megyei Kórház Kardiológiai Osztály
Kecskemét, 6000
Andrea Hornyik, MD
Miskolc, 3529
Pécsi Tudomány Egyetem Klinikai Központ, I. sz. Belgyógyászati Klinika,
Pécs, 7624
Jász-Nagykun-Szolnok Megyei Hetény i Géza Kórház Kardiológiai Osztály
Szolnok, 5000
Belvárosi Egészségház Kft
Zalaegerszeg, 8900
Czechia7 sites
Interni kardiologicka klinika FN Brno
Brno, 625 00
Kardiologicka ambulance
Chlumec nad Cidlinou, 50353
Centrum preventivní kardiologie, Karlovo nám. 32,
Prague, 128 08
Centrum preventivní kardiologie
Prague, 128 08
General University Hospital in Prague
Prague, 128 08
General University Hospital
Prague, 128 08
IKEM-Klinika kardiologie
Prague, 140 21
Latvia4 sites
Daugavpils Regional Hospital
Daugavpils, LV5417
Liepajas Regional Hospital
Liepāja, LV3414
Pauls Stradins Clinical University Hospital
Riga, LV1002
Riga East University hospital clinic Gailezers
Riga, LV1038
Lithuania3 sites
The Hospital of Lithuanian
Kaunas, 50161
Klaipeda Seaman's Hospital
Klaipėda, 92288
Vilnius University Hospital Santaros Klinikos
Vilnius, 08661
About this study
Official title: A Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency /and Sub-Study
The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo in the treatment of participants in heart failure with a reduced ejection fraction and with iron deficiency
Read the detailed description
This is a double-blind, multicenter, prospective, randomized, placebo-controlled study to assess the effects of IV FCM compared to placebo on the 12-month rate of death, hospitalization for worsening heart failure, and the 6-month change in 6 minute walk test (6MWT) distance for patients in heart failure with iron deficiency.
After an initial screening period of up to 28 days, eligible participants will be stratified by region and randomized in a 1:1 ratio to FCM or placebo for treatment.
Study drug administration will occur on Day 0 and Day 7 (±2) as an undiluted slow IV push, with additional study visits planned at 3 month intervals, and additional dosing administered every 6 months as applicable. In a subset of sites, a sub-study will be conducted to characterize serum phosphate levels over time in participants with heart failure and iron deficiency after dosing with FCM. For all participants, hematology, ferritin, and transferrin saturation (TSAT), with appropriate safety evaluations, to determine additional treatment, will occur at 6 month intervals.
- Conditions
- Heart Failure, Iron-deficiency
- Being tested
- Ferric Carboxymaltose, Placebo
- Medical subject headings
- Heart Failure, Anemia, Iron-Deficiency
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ferric CarboxymaltoseDrug
Also called Injectafer, Ferinject
Intravenous Iron
PlaceboDrug
Also called Saline solution
Normal Saline Solution
| Study group | Role | What they receive |
|---|---|---|
| Ferric Carboxymaltose | Active comparator | Ferric Carboxymaltose 2 doses intravenously of 15mg/kg to a maximum individual dose of 750mg 7 days apart and a maximum combined dose of 1500mg - repeated every 6 months as indicated by the results of iron indices. Receives: Drug: Ferric Carboxymaltose |
| Placebo | Placebo comparator | Normal saline 15ml - 2 doses 7 days apart repeated every 6 months. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Deaths
The number of participants who died out of the total treated group.
Measured: 1 year
Number of Hospitalizations for Heart Failure
The number of participants who were hospitalized for heart failure out of the total treated group.
Measured: 1 year
Change in 6MWT (Six Minute Walk Test) Distance
The change in meters walked at baseline compared to 6 months later.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jan 2017 (estimated)
- Study start15 Mar 2017
- Primary completion2 Feb 2023
- Study completion2 Feb 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 3,065 participants (actual)
Sponsor and investigators
- Lead sponsor
- American Regent, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Duke Clinical Research Institute
- Responsible party
- Sponsor
- Investigators
- Adrian F Hernandez, MD, Study chair, Duke Clinical Research Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03037931
- Sponsor's protocol ID
- 1VIT15043
- Acronym
- HEART-FID
- Status last verified
- Feb 2024
- First submitted
- 25 Jan 2017
- Last updated
- 3 Jul 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Lewis GD, Giczewska A, Mentz RJ, Butler J, Ezekowitz JA, De Pasquale C, O'Meara E, Troughton RW, Ponikowski P, Wong YW, Ikoma T, Malhotra R, Blackman N, Rockhold FW, Hernandez AF; HEART-FID Trial Investigators. Functional and Prognostic Implications of Different Iron Deficiency Definitions in Heart Failure: Insights From HEART-FID. JACC Heart Fail. 2025 Dec;13(12):102661. doi: 10.1016/j.jchf.2025.102661. Epub 2025 Oct 25.
PubMed 41137844Ezekowitz JA, Mulder H, Mentz RJ, Butler J, DE Pasquale CG, Lewis GD, O'Meara E, Ponikowski P, Troughton RW, Wong YW, Adamczyk R, Numan S, Blackman N, Rockhold FW, Hernandez AF. Prediction and Longer-Term Outcomes of All-cause and Cardiovascular Mortality in the HEART-FID Trial. J Card Fail. 2025 Dec;31(12):1822-1833. doi: 10.1016/j.cardfail.2025.01.009. Epub 2025 Jan 29.
PubMed 39890013Harrington J, Mentz RJ, Rockhold FW, Garg J, Butler J, De Pasquale CG, Ezekowitz JA, Lewis GD, O'Meara E, Ponikowski P, Troughton RW, Wong YW, Adamczyk R, Storie T, Blackman N, Hernandez AF. Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial. Circ Heart Fail. 2024 Feb;17(2):e010676. doi: 10.1161/CIRCHEARTFAILURE.123.010676. Epub 2024 Jan 22.
PubMed 38250799Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA, Lewis GD, O'Meara E, Ponikowski P, Troughton RW, Wong YW, She L, Harrington J, Adamczyk R, Blackman N, Hernandez AF; HEART-FID Investigators. Ferric Carboxymaltose in Heart Failure with Iron Deficiency. N Engl J Med. 2023 Sep 14;389(11):975-986. doi: 10.1056/NEJMoa2304968. Epub 2023 Aug 26.
PubMed 37632463Harrington J, Mentz RJ, Rockhold FW, Garg J, Butler J, De Pasquale CG, Ezekowitz JA, Lewis GD, O'Meara E, Ponikowski P, Troughton RW, Wong YW, Adamczyk R, Blackman N, Hernandez AF. Baseline characteristics of patients in the randomized study to investigate the efficacy and safety of ferric carboxymaltose as treatment for heart failure with iron deficiency: HEART-FID trial. Am Heart J. 2023 Dec;266:25-31. doi: 10.1016/j.ahj.2023.08.005. Epub 2023 Aug 19.
PubMed 37598795Mentz RJ, Ambrosy AP, Ezekowitz JA, Lewis GD, Butler J, Wong YW, De Pasquale CG, Troughton RW, O'Meara E, Rockhold FW, Garg J, Samsky MD, Leloudis D, Dugan M, Mundy LM, Hernandez AF; HEART-FID Trial Investigators. Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. Circ Heart Fail. 2021 May;14(5):e008100. doi: 10.1161/CIRCHEARTFAILURE.120.008100. Epub 2021 May 18.
PubMed 34003690
Study at a glance
From the registry record, last updated by the sponsor on 3 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency /and Sub-Study
- ClinicalTrials.gov ID
- NCT03037931
- Acronym / sponsor ID
- HEART-FID / 1VIT15043
- Conditions
- Heart Failure, Iron-deficiency
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 3,065 participants (actual)
- Lead sponsor
- American Regent, Inc.Industry (pharma, biotech, devices)
- Collaborators
- Duke Clinical Research Institute
- Study start
- 15 Mar 2017 (actual)
- Primary completion
- 2 Feb 2023 (actual)
- Study completion
- 2 Feb 2023 (actual)
- First posted
- 31 Jan 2017 (estimated)
- Results
- Posted 3 Jul 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo in the treatment of participants in heart failure with a reduced ejection fraction and with iron deficiency
Detailed description
This is a double-blind, multicenter, prospective, randomized, placebo-controlled study to assess the effects of IV FCM compared to placebo on the 12-month rate of death, hospitalization for worsening heart failure, and the 6-month change in 6 minute walk test (6MWT) distance for patients in heart failure with iron deficiency.
After an initial screening period of up to 28 days, eligible participants will be stratified by region and randomized in a 1:1 ratio to FCM or placebo for treatment.
Study drug administration will occur on Day 0 and Day 7 (±2) as an undiluted slow IV push, with additional study visits planned at 3 month intervals, and additional dosing administered every 6 months as applicable. In a subset of sites, a sub-study will be conducted to characterize serum phosphate levels over time in participants with heart failure and iron deficiency after dosing with FCM. For all participants, hematology, ferritin, and transferrin saturation (TSAT), with appropriate safety evaluations, to determine additional treatment, will occur at 6 month intervals.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Ferric Carboxymaltose | Active comparator | Drug: Ferric CarboxymaltoseFerric Carboxymaltose 2 doses intravenously of 15mg/kg to a maximum individual dose of 750mg 7 days apart and a maximum combined dose of 1500mg - repeated every 6 months as indicated by the results of iron indices. |
| Placebo | Placebo comparator | Drug: PlaceboNormal saline 15ml - 2 doses 7 days apart repeated every 6 months. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Adult (≥18 years of age) able to provide signed, written informed consent.
- Stable heart failure (NYHA II-IV) on maximally-tolerated background therapy (as determined by the site Principle Investigator) for at least 2 weeks prior to randomization.
- Able and willing to perform a six-minute walk test (6MWT) at the time of randomization.
- Reduced left ventricular ejection fraction. Assessment must be performed at least 12 weeks after major cardiac surgical intervention including coronary artery bypass graft (CABG), valvular repair/replacement, or cardiac resynchronization therapy (CRT) device implantation.
- Hemoglobin >9.0 g/dL and < 13.5 g/dL (females) or <15.0 g/dL (males) within 28 days of randomization.
Key exclusion criteria (14 listed)
- Known hypersensitivity reaction to any component of FCM.
- History of acquired iron overload, or the recent receipt (within 3 months) of erythropoietin stimulating agent, IV iron therapy, or blood transfusion.
- Acute myocardial infarction, acute coronary syndrome, transient ischemic attack, or stroke within 30 days of enrollment.
- Uncorrected severe aortic stenosis, severe valvular regurgitation (except mitral regurgitation due to left ventricular dilatation without planned intervention), or left ventricular outflow obstruction requiring intervention.
- Current atrial fibrillation or atrial flutter with a mean ventricular response rate >100 per minute (at rest).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ferric CarboxymaltoseAlso: Injectafer, FerinjectIntravenous Iron | Drug | Ferric Carboxymaltose |
| PlaceboAlso: Saline solutionNormal Saline Solution | Drug | Placebo |
Primary outcome
Number of Deaths
Time frame: 1 year
The number of participants who died out of the total treated group.
Number of Hospitalizations for Heart Failure
Time frame: 1 year
The number of participants who were hospitalized for heart failure out of the total treated group.
Change in 6MWT (Six Minute Walk Test) Distance
Time frame: 6 months
The change in meters walked at baseline compared to 6 months later.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Jul 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 41137844Lewis GD, Giczewska A, Mentz RJ, Butler J, Ezekowitz JA, De Pasquale C, O'Meara E, Troughton RW, Ponikowski P, Wong YW, Ikoma T, Malhotra R, Blackman N, Rockhold FW, Hernandez AF; HEART-FID Trial Investigators. Functional and Prognostic Implications of Different Iron Deficiency Definitions in Heart Failure: Insights From HEART-FID. JACC Heart Fail. 2025 Dec;13(12):102661. doi: 10.1016/j.jchf.2025.102661. Epub 2025 Oct 25.
- Derived from this study: PubMed 39890013Ezekowitz JA, Mulder H, Mentz RJ, Butler J, DE Pasquale CG, Lewis GD, O'Meara E, Ponikowski P, Troughton RW, Wong YW, Adamczyk R, Numan S, Blackman N, Rockhold FW, Hernandez AF. Prediction and Longer-Term Outcomes of All-cause and Cardiovascular Mortality in the HEART-FID Trial. J Card Fail. 2025 Dec;31(12):1822-1833. doi: 10.1016/j.cardfail.2025.01.009. Epub 2025 Jan 29.
- Derived from this study: PubMed 38250799Harrington J, Mentz RJ, Rockhold FW, Garg J, Butler J, De Pasquale CG, Ezekowitz JA, Lewis GD, O'Meara E, Ponikowski P, Troughton RW, Wong YW, Adamczyk R, Storie T, Blackman N, Hernandez AF. Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial. Circ Heart Fail. 2024 Feb;17(2):e010676. doi: 10.1161/CIRCHEARTFAILURE.123.010676. Epub 2024 Jan 22.
- Derived from this study: PubMed 37632463Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA, Lewis GD, O'Meara E, Ponikowski P, Troughton RW, Wong YW, She L, Harrington J, Adamczyk R, Blackman N, Hernandez AF; HEART-FID Investigators. Ferric Carboxymaltose in Heart Failure with Iron Deficiency. N Engl J Med. 2023 Sep 14;389(11):975-986. doi: 10.1056/NEJMoa2304968. Epub 2023 Aug 26.
- Derived from this study: PubMed 37598795Harrington J, Mentz RJ, Rockhold FW, Garg J, Butler J, De Pasquale CG, Ezekowitz JA, Lewis GD, O'Meara E, Ponikowski P, Troughton RW, Wong YW, Adamczyk R, Blackman N, Hernandez AF. Baseline characteristics of patients in the randomized study to investigate the efficacy and safety of ferric carboxymaltose as treatment for heart failure with iron deficiency: HEART-FID trial. Am Heart J. 2023 Dec;266:25-31. doi: 10.1016/j.ahj.2023.08.005. Epub 2023 Aug 19.
- Derived from this study: PubMed 34003690Mentz RJ, Ambrosy AP, Ezekowitz JA, Lewis GD, Butler J, Wong YW, De Pasquale CG, Troughton RW, O'Meara E, Rockhold FW, Garg J, Samsky MD, Leloudis D, Dugan M, Mundy LM, Hernandez AF; HEART-FID Trial Investigators. Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. Circ Heart Fail. 2021 May;14(5):e008100. doi: 10.1161/CIRCHEARTFAILURE.120.008100. Epub 2021 May 18.
- Individual participant dataSharing planned: No
Related trials for Heart Failure
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Recruiting
Evaluation of a French Hospital Discharge Therapeutic Education Program by Nurses for Heart Failure Patient (EduSor)
Heart Failure
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruiting
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Adrian F Hernandez, MD study chair
Duke Clinical Research Institute
345 sites in 13 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Ferric Carboxymaltose in people with Heart Failure and Iron-deficiency, run by American Regent, Inc. at 345 sites in 13 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 345 sites in United States, Canada, Ukraine, Australia, Poland and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 3 Jul 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Deaths (time frame: 1 year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03037931, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jul 2024.